ChronoScale Holdings Corp (CHRN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Board Resignation of and Release Agreement with Mr. Davis As previously announced, on September 30, 2026, ChronoScale Hold

Event · Exec change
Person
Scott Davis
Title
member of the Board of Directors
Action
resigned
Effective
October 3, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 6, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CHRN
Bearish
high confidence
Mentioned
$CHRN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CHRNBearishLow
01

Why it matters

The leadership change may lead to short‑term volatility, but the cash payment is modest relative to the company's assets, suggesting limited long‑term impact.

02

Market read

A small‑cap corporate action that may cause modest price movement; primarily relevant to CHRN shareholders and short‑term traders.

03

What to watch

The payment is funded by cash reserves and does not affect the company's balance sheet materially.

Relevance 6/10Novelty 6/10Timing: today

Background

ChronoScale Holdings Corp (CHRN) completed the sale of its subsidiary Ekso Bionics and subsequently filed an 8‑K detailing the resignation of board member Scott Davis and his compensation package.

Company-level read

Ticker impact

$CHRNBearishHigh confidence
Context

ChronoScale Holdings Corp filed an 8‑K reporting the resignation of board member Scott Davis and a $709,500 cash severance payment.

Expected impact

likely slight pressure as the market prices in the leadership change and cash outflow.

Evidence & confidence

The filing is the first public disclosure of the resignation and payment; such events typically trigger a modest sell‑off in small‑cap stocks.

Market effects

Minimal impact on the broader med‑tech sector; the event is company‑specific.

Limited to U.S. small‑cap investors; no broader regional effect.

None

Counterpoint

The severance could be seen as a clean break that allows new leadership to pursue growth, potentially supporting the stock.

Key entities

  • ChronoScale Holdings Corp

    Publicly listed U.S. company (ticker CHRN) reporting a director resignation.

  • Scott Davis

    Former board member and CEO of Ekso Bionics receiving severance.

Related articles

$SLNHMed

Soluna and Applied Digital to build 50 MW wind-powered AI data center in Texas

Soluna (SLNH) and Applied Digital (APLD) agreed to form a joint venture to build a 50 MW wind-powered AI data center in Texas. Applied will own 51%, providing capital, while Soluna contributes land and power assets. ChronoScale (CHRN), majority-owned by Applied, may lease the facility. The project is expected to close by year-end, with Phase 1 powered by Soluna's Briscoe Wind Farm and the grid.

$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

$CHRNMed

ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.